Edition:
India

Gemphire Therapeutics Inc (GEMP.OQ)

GEMP.OQ on NASDAQ Stock Exchange Global Market

9.00USD
22 Nov 2017
Change (% chg)

$-0.23 (-2.49%)
Prev Close
$9.23
Open
$9.32
Day's High
$9.32
Day's Low
$8.96
Volume
11,729
Avg. Vol
31,590
52-wk High
$21.59
52-wk Low
$7.22

Chart for

About

Gemphire Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. It is developing its product candidate, gemcabene (CI-1027), which is a once-daily, oral therapy for patients who are unable to... (more)

Overall

Beta: --
Market Cap(Mil.): $110.31
Shares Outstanding(Mil.): 10.63
Dividend: --
Yield (%): --

Financials

BRIEF-Gemphire Therapeutics reports qtrly loss of $0.82‍​/shr

* Gemphire Therapeutics Inc qtrly loss per share $0.82‍​ Source: (http://bit.ly/2iaJuNF) Further company coverage:

13 Nov 2017

BRIEF-Gemphire announces plans to advance gemcabene into phase 3 clinical development

* Gemphire announces plans to advance gemcabene into phase 3 clinical development

20 Sep 2017

BRIEF-Gemphire Therapeutics Inc files mixed shelf of up to $175 million - SEC filing ‍​

* Gemphire therapeutics inc files mixed shelf of up to $175 million - SEC filing ‍​ Source text: (http://bit.ly/2vRDX2x) Further company coverage:

02 Sep 2017

BRIEF-Gemphire Therapeutics Inc posts Q2 net loss $0.99/shr

* Gemphire announces second quarter 2017 financial results and provides corporate update

14 Aug 2017

BRIEF-Gemphire announces top-line data from royal-1 phase 2b clinical trial in hypercholesterolemic patients

* Gemphire announces top-line data from royal-1 phase 2b clinical trial in hypercholesterolemic patients

07 Aug 2017

BRIEF-Gemphire enters into $15 mln term loan agreement with Silicon Valley Bank

* Gemphire enters into $15 million term loan agreement with silicon valley bank

25 Jul 2017

BRIEF-Gemphire Therapeutics reports departure of CEO

* Gemphire Therapeutics announces departure of its chief executive officer Mina Sooch

31 May 2017

Earnings vs. Estimates